XENOTHERA is a biotechnologies company at the top of innovation, which creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases.
Our technological platform is built on a double expertise of animal genetics and mastery of immunology processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera.
XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of interesting immunoglobulins, and access to market authorization in accelerated timescale.
PROOF OF CONCEPT
SERIE A FUNDRAISING